NCT00851838已完成2 期
Phase 2 Study of Dialysis Efficiency and Tolerability of Peritoneal Dialysis Solution Containing Glucose Plus L-Carnitine in APD (Automated Peritoneal Dialysis) Treated Uremic Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- To assess the efficacy of L-Carnitine containing PD solution on peritoneal ultrafiltration
研究概览
简要总结
A major challenge of peritoneal dialysis (PD) therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration (UF) profile. Study hypothesis is to evaluate the possibility to formulate PD solutions containing L-carnitine as an osmotic agent to partially replace glucose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years
- •Have a diagnosis of ESRD and have been on Automated Peritoneal Dialysis (glucose 1.5 or 2.5 % w/v) for at least 3 months
- •Be in a stable clinical condition during the four weeks immediately prior to Screening Period as demonstrated by medical history, physical examination and laboratory testing
- •Have a blood hemoglobin concentration above 8,5 g/100ml (data will be verified with Investigators)
- •Have not experienced peritonitis episodes in the last 3 months
- •Have Kt/V urea measurement > 1.7 per week in a previous test performed within 6 months that should be confirmed at Baseline Visit
- •Have a minimum weekly creatinine clearance of 45 litres in a previous test performed within 6 months that should be confirmed at Baseline Visit
- •Have a D/P Creatinine ratio at Peritoneal Equilibration Test (PET) between 0.50 and 0.81 in a previous test performed within 6 months that should be confirmed at Baseline Visit
- •Have a D/P Glucose ratio at Peritoneal Equilibration Test (PET) between 0.26 and 0.49 in a previous test performed within 6 months that should be confirmed at Baseline Visit
- •Be treated by the participating clinical Investigator for a period of at least three months
- •Have understood and signed the Informed Consent Form.
排除标准
- •Have a history of drug or alcohol abuse in the six months prior to entering the protocol
- •Be in treatment with androgens
- •Have Diabetes Mellitus (as defined by the American Diabetes Society, objectively documented by a fasting plasma glucose and HbA1c determinations)
- •Have clinically significant abnormal liver function test (SGOT, SGPT, and gamma-GT > 2 times the upper normal limit)
- •Have acute infectious conditions (i.e.: pulmonary infection, acute hepatitis, high or low urinary tract infections, renal parenchymal infection, pericarditis, etc)
- •Have a history of congestive heart failure and clinically significant arrhythmia
- •Have an history of epilepsy or any NCS disease
- •Have malignancy within the past 5 years, including lymphoproliferative disorders
- •Have any medical condition that, in the judgment of the Investigator, would jeopardize the patient's safety following exposure to study drug, particularly if patient's life expectancy is less than 1 year
- •Have a history of L-Carnitine therapy or use in the month prior to entering the protocol
- •Have used any investigational drug in the 3 months prior to entering the protocol
- •Be in pregnancy, lactation, fertility age without protection against pregnancy by adequate contraceptive means
研究组 & 干预措施
PD solution
Experimental
干预措施: L-Carnitine (Drug)
结局指标
主要结局
To assess the efficacy of L-Carnitine containing PD solution on peritoneal ultrafiltration
时间窗: day 5
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Study of Safety and Efficacy on New Peritoneal Dialysis SolutionsEnd-Stage Renal DiseaseNCT00858182Iperboreal Pharma Srl
已完成
2 期
L-Carnitine in Peritoneal DialysisEnd-Stage Renal DiseaseNCT00922701Iperboreal Pharma Srl4
Unknown
不适用
Improving the Outcomes of Peritoneal Dialysis (PD) Catheter InsertionPeritoneal Dialysis Access FailurePeritoneal Dialysis ComplicationNCT04034628Sunnybrook Health Sciences Centre2,320
已完成
不适用
Observational Study of Glucose Metabolism and How Dialysate Glucose Affects ThisGlucose Metabolism DisordersNCT02042768Keele University1,451
Unknown
不适用
Peritoneal Dialysis as an Option of Unplanned Initiation of Chronic DialysisDisorders Associated With Peritoneal DialysisNCT02646436Universidade Estadual Paulista Júlio de Mesquita Filho188